Follistatin

Follistatin is an endogenous glycoprotein that acts as a potent antagonist of myostatin (also called GDF-8), a member of the TGF-β superfamily that inhibits muscle growth. Two follistatin isoforms exist from alternative splicing: FS-317 and FS-344. Post-translational modification of FS-344 produces the FS-315 circulating isoform with reduced heparin binding and reduced effects on the gonadal-pituitary axis. FS-344 is the isoform that has been pursued through gene-therapy clinical trials by James Chamberlain, Jerry Mendell, and colleagues at Nationwide Children's Hospital. The "follistatin peptide" sold by research-chemical vendors is a synthetic FS-315 or FS-344 protein, distinct from the AAV-mediated gene-therapy approach.

Native human follistatin is a glycoprotein of approximately 300 amino acids. The molecule is too large to be a "small peptide" in the conventional sense and is more accurately described as a small protein. It binds myostatin and other TGF-β family members (activins, GDF-11) with high affinity, preventing their interaction with type II activin receptors and blocking the downstream signaling that normally inhibits muscle growth.

The clinical interest in follistatin originated from observations in 1997 that mice genetically engineered to lack myostatin developed approximately twice the normal muscle mass. Similar phenotypes were observed in cattle (Belgian Blue breed), sheep, dogs, and rare human cases. Follistatin emerged as the most potent natural myostatin antagonist and the most practical target for therapeutic myostatin inhibition.

The Gene Therapy Trials

The Phase 1/2a clinical-trial program for follistatin has used AAV1-delivered FS-344 rather than direct injectable peptide administration.

Becker muscular dystrophy (Mendell et al., Molecular Therapy, 2015). Six BMD patients received AAV1.CMV.FS344 delivered by direct bilateral intramuscular quadriceps injections at two dose levels (Cohort 1: 3 × 10¹¹ vg/kg/leg; Cohort 2: 6 × 10¹¹ vg/kg/leg). The primary outcome was the 6-minute walk test (6MWT). Patient 01 improved 58 meters at 1 year; Patient 02 improved 125 meters. The trial established proof of concept for AAV-mediated follistatin gene therapy in muscular dystrophy.

Sporadic Inclusion Body Myositis (sIBM). A separate Phase 1/2a trial in sIBM patients used a similar AAV1-FS-344 approach. Post-treatment biopsies showed reduced fibrosis and improved functional outcomes. The trial established the anti-fibrotic dimension of the follistatin effect.

Duchenne muscular dystrophy. Preclinical work in mdx mice (the standard DMD model) using AAV1-FS-344 shown increased muscle mass, improved strength, and delayed muscle deterioration with effects lasting over 2 years. Clinical development for DMD has been the next step in the gene-therapy pipeline.

The trial program is small. Phase 3 efficacy trials in muscular dystrophy have not yet completed. The gene therapy approach has not received FDA approval for any indication. Other myostatin inhibitors (monoclonal antibodies like landogrozumab, domagrozumab, and trevogrumab) have been pursued by major pharmaceutical sponsors with mixed Phase 2/3 results.

Follistatin's mechanism centers on myostatin antagonism plus broader effects on other TGF-β family members.

Myostatin binding and inhibition. Native myostatin binds activin type II receptors (ActRIIB primarily) on muscle cells, triggering SMAD2/3 phosphorylation and downstream signaling that limits muscle protein synthesis and satellite cell activation. Follistatin binds myostatin with high affinity, preventing its receptor engagement. The result is dis-inhibition of muscle growth pathways.

Activin binding and effects on inflammation. Follistatin also binds activin A and activin B, which have roles in inflammation, fibrosis, and immune regulation. The activin-binding effect contributes to anti-inflammatory effects and reduced fibrosis in muscle, which is relevant in muscular dystrophies and inflammatory myopathies.

Independent muscle growth pathways. Beyond myostatin inhibition, follistatin appears to support muscle growth through pathways that are at least partly independent of myostatin signaling. Myostatin-null mice carrying a follistatin transgene show approximately four times normal muscle mass, whereas myostatin-null mice alone show approximately twice normal mass. The additional doubling suggests follistatin acts through additional mechanisms.

Reduced fibrosis. In muscle biopsies from follistatin-treated patients (the Phase 1/2a sIBM trial), post-treatment biopsies showed histological evidence of decreased fibrosis along with downregulation of fibrosis markers including TGF-β, Col1A, and fibronectin.

Regulatory status

Follistatin has no FDA approval, no EMA approval, and no marketing authorization in any country for any product configuration (gene therapy or injectable peptide).

The injectable peptide is not on the FDA Category 2 bulks list as of May 2026, which is unusual for a non-approved compound but may reflect the complexity of regulating a small protein versus a defined peptide. Compounding pharmacy availability is limited.

The gene therapy approach (AAV1-FS-344) has been the subject of FDA IND filings for Becker muscular dystrophy and sporadic inclusion body myositis. Phase 1/2a trials have completed. Phase 3 registrational trials have not been completed.

Follistatin is on the WADA Prohibited List under section S4.4 (Agents Affecting Myostatin Function). Use in competitive sport is a doping violation. The WADA listing applies to all myostatin inhibitors, including the gene therapy approaches and injectable products.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The Phase 1/2a gene therapy trials reported a generally clean safety profile in BMD and sIBM patients. No serious systemic toxicity has emerged in the small published clinical datasets. The AAV1 vector has the immunological safety profile typical of AAV-mediated gene therapy (some risk of vector-induced immune response, low risk of serious adverse events with the doses tested).

For injectable peptide use, the safety database is largely anecdotal. Adult research settings report:

Theoretical cardiac concerns. Myostatin inhibition in some animal models has produced cardiac hypertrophy and reduced exercise capacity. The clinical signal in humans has been small but warrants attention with prolonged use.

Theoretical reproductive concerns. The FS-315 circulating isoform was specifically selected to minimize effects on the gonadal-pituitary axis (compared with the FS-317 isoform that has stronger heparin binding and higher reproductive risk). The injectable peptide products sold commercially are not always specified as FS-315 or FS-344, and the regulatory cleanness that pharmaceutical-grade FS-344 provides may not apply.

Injection-site reactions. Common with subcutaneous peptide administration.

Mild gastrointestinal effects at higher doses.

The long-term safety of myostatin inhibition in healthy adults is not characterized. The trial populations have been muscular dystrophy patients with substantial baseline muscle pathology, not healthy individuals seeking muscle hypertrophy. Whether the safety findings translate to healthy adult use is unknown.

The myostatin inhibitor class includes several approaches with different evidence and regulatory positions.

Follistatin (FS-344 gene therapy). The most extensively studied gene therapy approach. Phase 1/2a data in BMD and sIBM. No FDA approval yet. The strongest data among myostatin-targeting approaches in muscular dystrophy.

Landogrozumab, domagrozumab, trevogrumab (monoclonal antibodies to myostatin). Pursued by Eli Lilly, Pfizer, and Regeneron through Phase 2/3 trials in muscular dystrophy and sarcopenia. Mixed results. No FDA approval at the time of writing.

Bimagrumab (monoclonal antibody to ActRIIA/IIB). Targets the receptor rather than myostatin directly. Phase 2 trials in sarcopenia and inclusion body myositis. Development has been variable. Currently being developed for obesity by Versanis (now Eli Lilly).

Apitegromab (SRK-015). A myostatin-targeting antibody in spinal muscular atrophy (SMA), with Phase 3 trial data and active development.

For muscular dystrophy specifically, the myostatin inhibitor class has not produced an FDA-approved option as of May 2026. The follistatin gene therapy approach has the most positive small-trial data but has not progressed to registrational Phase 3 readouts.